Search Login Register

Raloxifene (Evista) Summary

Description: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Also Known As: Evista; ELi Lilly Brand of Raloxifene; Keoxifene; Keoxifene Hydrochloride; LY 139481 Show All >>

Networked: 1018 relevant articles (108 outcomes, 318 trials/studies) for this Drug

Key Diseases for which Raloxifene is Relevant

  1. Breast Neoplasms (Breast Cancer) : 47 outcomes 131 studies in 372 results
  2. Osteoporosis : 39 outcomes 121 studies in 418 results
  3. Postmenopausal Osteoporosis : 7 outcomes 13 studies in 122 results
  4. Neoplasms (Cancer) : 6 outcomes 14 studies in 75 results
  5. Metabolic Bone Diseases (Osteopenia) : 3 outcomes 7 studies in 30 results
Show All >>

Drugs Related to Raloxifene

  1. Tamoxifen
  2. Selective Estrogen Receptor Modulators (SERM)
  3. Estrogens (Estrogen)
  4. Alendronate (Alendronate Sodium)
  5. Estradiol (Estrace)
  6. risedronic acid (risedronate)
  7. Diphosphonates
  8. Raloxifene (Evista)
  9. Calcitonin (Calcitonin, Eel)
  10. Biological Markers (Surrogate Marker)
Show All >>

Therapies Related to Raloxifene

  1. Chemoprevention
  2. Hysterectomy
  3. Estrogen Replacement Therapy
  4. Drug Therapy (Chemotherapy)
  5. Female Contraceptive Devices (Vaginal Ring)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2010 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.